In Vitro Detection of Tissue Abnormality

Not Applicable

Completed

• Conditions: Breast Cancer Female
• Interventions: Device: Testing a new device (LS BioPath TOUCH) on excised tissue

• Registration Number: NCT01209182
• Lead Sponsor: LS BioPath

Brief Summary

Intraoperative ex-vivo use of the ClearEdge Imaging Device in Breast Conserving Surgery to image the excised tissue surgical margins. The study is designed to demonstrate reduction in the need for repeat surgeries after breast conserving surgeries by using the ClearEdge as an adjunct imaging device to the standard of care.

Detailed Description

Intraoperative real-time margin assessment of breast conserving surgeries can reduce the need for repeat operations due to cancer involved margins. Repeat operations result in excessive removal of benign tissue, increased risk for infection, slower healing and inferior cosmetic results. In the current standard of care, the status of the margins is determined by pathology only several days after surgery. An intraoperative assessment of the margins enables complete tumor excision in a single surgery.

The proposed randomized controlled study will evaluate the benefits of adding the ClearEdge imaging device to the Standard of Care (SoC) of margins assessment in breast conserving surgeries. The study will assess whether there is an improvement in the detection of cancer involved margins by measuring whether removal at the time of primary surgical treatment can reduce the need for repeat surgeries as compared to the SoC, which does not use the device.

ClearEdge is a CE marked device already been used in several hospitals in the UK. It was used in a prospective single arm and 2 phases clinical study. It was demonstrated that surgeons successfully used the device to identify cancer involved margins and that it can reduce the need for repeat surgeries by meeting the margins depth criteria to require repeat operations. European Journal of Oncology Surgery. 2016; 42 (12): 1834-1840. In addition, the device was clinically evaluated by several hospitals.

Study Timeline

• Study First Submitted: 2010-09-21
• Study First Submitted QC: 2010-09-23
• Study First Posted: 2010-09-27
• Study Start: 2010-10-15
• Primary Completion: 2011-12-13
• Study Completion: 2012-01-09
• Status Verified: 2022-04
• Last Update Submitted: 2022-09-29
• Last Update Posted: 2022-10-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 121

Inclusion Criteria

• Patients aged 25-80 who are scheduled for surgical excision of tissue.

Exclusion Criteria

• No prior history of surgery at location of current surgery.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Device image reading	Testing a new device (LS BioPath TOUCH) on excised tissue	Tissue images generated by the device are read by surgeons to determine if the tissue area under test has abnormal component or not. When Images generated by the device are read by surgeons as abnormal an additional margin of tissue is removed. The new margin is also imaged by the device to ensure complete tumor excision.

Primary Outcome Measures

Name	Time	Method
•Accuracy of LS BioPath TOUCH device compared to pathology	1 week after surgery	Assess percentage of FP and FN of test device results compared to pathology results

Trial Locations

Locations (1)

St. Mary's; 🇺🇸 San Francisco, California, United States